NABI BIOPHARMACEUTICALS : VPRO - Viropro Inc +2700% en janvier

Profil supprimé

21 janv. 2011 •17:29

va falloir la surveiller de près celle-là...

qqchose me dit qu'elle en a encore sous le capot
;-)

http://www.mystockbuddy.com/forum/biopharmaceutical_picks/3964-vpro_virop ro_inc.html



Viropro, Inc. (Viropro) conducts operations through its subsidiary, Viropro International Inc., and specializes in the transfer of its technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, including cancer, diabetes, hepatitis or multiple sclerosis. The company’s principal focus is to provide manufacturing process technology transfers to biotech and pharmaceutical companies in global markets with unmet medical needs. Viropro's platform technology allows it to develop manufacturing processes for biotech products. The platform also allows the Company to undertake contractual development for biotechnology and biopharmaceutical manufacturing companies, and develop or co-develop products with partnering companies. The markets that Viropro focuses on include South America, Northern Africa and Asia (mainly India).


Open $0.01
Close $0.14

+2,700.00%

The news:
Spectrum Pharma in pact to develop generic Rituxan

January 5, 2011 12:28 PM ET
IRVINE, Calif. (AP) - Drugmaker Spectrum Pharmaceuticals Inc. said Wednesday it will develop a biosimilar version of the cancer drug Rituxan through a new partnership with Viropro Inc.

Financial terms weren't disclosed.

Rituxan, or rituximab, is approved to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. It is sold by the Genentech unit of Swiss drugmaker Roche Holding, and by Biogen Idec Inc. Spectrum said worldwide sales totaled $5.6 billion in 2009. The drug is sold under the name MabThera in other markets.

Biosimilars are copies of biotech-based drugs and are to biotech drugs what generic drugs are to traditional chemical-based pharmaceuticals. New regulations in the U.S. have set up a path for approval of biosimilars, and generics are poised to eventually break into that new market.

Spectrum makes the lymphoma drug Zevalin. It acquired the drug from Biogen Idec in 2007, and in a recent clinical trial, Spectrum said lymphoma patients who were treated with Zevalin following chemotherapy lived longer than patients who were treated with chemotherapy and Rituxan, or chemotherapy alone.

Spectrum and Viropro are both headquartered in Irvine, Calif.